|
Synonyms: compound (+)-16a [PMID: 25633969]
Compound class:
Synthetic organic
Comment: Lumocaserin is the INN for a serotonin 5-HT2C receptor agonist, with anti-epileptic potential. The structure provided in the INN record is identical to that for compound (+)-16a in [2], and additional 2-phenylcyclopropylmethylamine-based 5-HT2C agonists similar to lumocaserin are described in [3]. Analysis of available patent and peer-reviewed information around compounds with this core structural scaffold strongly suggests that lumocaserin is the INN for Bright Minds Biosciences' clinical candidate BMB-101, which is in development as an anti-epileptic agent. BMB-101 exhibits bias for Gq-mediated signaling. It does not induce β-arrestin recruitment and therefore does not cause 5-HT2C receptor desensitization.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Bialer M, Johannessen Landmark C, Koepp MJ, Perucca E, Perucca P, Tomson T, White HS, Wirrell E. (2026)
Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development. Epilepsia, 67 (10): 5075-5125. [PMID:42470359] |
|
2. Cheng J, Giguère PM, Onajole OK, Lv W, Gaisin A, Gunosewoyo H, Schmerberg CM, Pogorelov VM, Rodriguiz RM, Vistoli G et al.. (2015)
Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents. J Med Chem, 58 (4): 1992-2002. [PMID:25633969] |
|
3. Cheng J, Kozikowski AP. (2015)
We Need 2C but Not 2B: Developing Serotonin 2C (5-HT2C) Receptor Agonists for the Treatment of CNS Disorders. ChemMedChem, 10 (12): 1963-7. [PMID:26507582] |